n.a. (VRX)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 17.20 / 28.45
Exchange NYSE
Div & Yield N.A. (N.A)
Teva Still Hurts From Self-Inflicted Wounds

Teva Still Hurts From Self-Inflicted Wounds

It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.

Teva Still Hurts From Self-Inflicted Wounds

Teva Still Hurts From Self-Inflicted Wounds

It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.

Valeant's Decline May Be Over

Valeant's Decline May Be Over

An inverse head-and-shoulders pattern has formed, suggesting a bullish reversal.

Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap (Mon 9/25/17)

Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap (Mon 9/25/17)

Jim Cramer looks at the high-flying FANG stocks, and says he likes these companies best when their prices return to earth.

MGM Resorts, Baozun, DowDuPont, Wynn Resorts: 'Mad Money' Lightning Round

MGM Resorts, Baozun, DowDuPont, Wynn Resorts: 'Mad Money' Lightning Round

Jim Cramer is bullish on MGM Resorts, Baozun, DowDuPont, and Wynn Resorts.

ADP Is Morphing Into the IBM Blob: Bill Ackman

ADP Is Morphing Into the IBM Blob: Bill Ackman

The insurgent investor explains that he believes the payroll company's problems are yet to come.

Follow the Crucial '$20 Level Rule' When Trading Stocks

Follow the Crucial '$20 Level Rule' When Trading Stocks

Breaking below the $20 for the first time in years is a warning signal.

$20 Should Be Your Cutoff Point

$20 Should Be Your Cutoff Point

A stock that has been above $20 for years and then slips below $20 has a hard time finding new buyers.

Short the Stocks That Fall Below $20

Short the Stocks That Fall Below $20

A stock that has been above $20 for years, and then slips below $20, has a hard time finding new buyers.

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year

Can the beleaguered investor turn things around?

Beleaguered Hedge Fund Titan Bill Ackman Is Having Another Rough Year

Beleaguered Hedge Fund Titan Bill Ackman Is Having Another Rough Year

It certainly looks like 2017 is shaping up to be another "terrible, horrible, no good, very bad" year.

Valeant's Legal Bills Are Piling Up Following Latest Securities Fraud Lawsuit

Valeant's Legal Bills Are Piling Up Following Latest Securities Fraud Lawsuit

A mutual fund filed the lawsuit Wednesday.

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

For his 'Executive Decision' segment, Cramer again sat down with Joe Papa, chairman and CEO of Valeant

Mylan Finalizes $465 Million EpiPen Settlement With DoJ

Mylan Finalizes $465 Million EpiPen Settlement With DoJ

The dispute became the center of a drug price firestorm.

Valeant CEO Joe Papa Has Been Able to Pay Down Debt, Jim Cramer Explains

Valeant CEO Joe Papa Has Been Able to Pay Down Debt, Jim Cramer Explains

What's next for Valeant Pharmaceuticals shares?

ADP Is Just One of Bill Ackman's Biggest Bets

ADP Is Just One of Bill Ackman's Biggest Bets

You win some and you lose some.

The Market Is Not About Washington: Cramer's 'Mad Money' Recap (Wed 8/16/17)

The Market Is Not About Washington: Cramer's 'Mad Money' Recap (Wed 8/16/17)

Jim Cramer says despite chaos in Washington, the market's not falling. Why? Because stocks aren't a referendum on the presidency.

Valeant Pharmaceuticals: Cramer's Top Takeaways

Valeant Pharmaceuticals: Cramer's Top Takeaways

Joe Papa, chairman and CEO of Valeant Pharmaceuticals International, talks to Jim Cramer about his company's turnaround.

Valeant and Teva Share Similar Ambitions With Similar Pitfalls

Valeant and Teva Share Similar Ambitions With Similar Pitfalls

Here's what you need to know now for Wed., Aug. 9.

Valeant Isn't Out of Trouble Yet, Debt Remains Difficult to Curb

Valeant Isn't Out of Trouble Yet, Debt Remains Difficult to Curb

The Laval, Quebec-based pharmaceutical company updated its revenue guidance and maintained its adjusted Ebitda outlook.

Marriott, Holiday Inn Dip As On-Demand Economy Claims Next Victim -ICYMI Tues.

Marriott, Holiday Inn Dip As On-Demand Economy Claims Next Victim -ICYMI Tues.

Here's what you need to know now for Tuesday, Aug. 8.

Valeant Pops on Earnings Beat, Debt Reduction Effort

Valeant Pops on Earnings Beat, Debt Reduction Effort

Amgen, Compugen and Foundation Medicine were among the biotech stock movers in premarket trading on July 26.

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

FibroGen, Depomed and Valeant were among the biotech stock movers in premarket trading on Aug. 8.

The Dow, Google and Avis - 5 Things You Must Know Before the Market Opens Tuesday

The Dow, Google and Avis - 5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures point to a lower open for Wall Street on Tuesday.

The Eerie Resemblance Between Now and 1987

The Eerie Resemblance Between Now and 1987

Fearlessness has always led to corrections.

The Retail Apocalypse Is About to Descend on Wall Street This Coming Week

The Retail Apocalypse Is About to Descend on Wall Street This Coming Week

The focus remains on earnings while the season winds down.

Markets Calm Sunday Despite U.S.-North Korea Tensions

Markets Calm Sunday Despite U.S.-North Korea Tensions

The UN Security Council unanimously voted Saturday to sanction North Korea for ballistic missile tests, but currencies and futures barely budged.

ADP Rejects Ackman Demands as It Performs Seven Times Better Than He Does

ADP Rejects Ackman Demands as It Performs Seven Times Better Than He Does

As Ackman's fund, Pershing Square, pushing for control of the board at ADP, the company highlights that the fund has underperformed ADP in recent years.

P&G, Valeant Exemplify Wall Street's 'Overboarded' Problem; Musk Must Raise Funds

P&G, Valeant Exemplify Wall Street's 'Overboarded' Problem; Musk Must Raise Funds

Here's what you need to know now for Thursday, Aug. 3.

3 Things Embattled Activist Investor Bill Ackman Wants to See Happen at ADP

3 Things Embattled Activist Investor Bill Ackman Wants to See Happen at ADP

Ackman seeks to take five of ten seats on the human resources company's board. Here's what he really wants.